/
ARDX
$5.23-$0.32 (-5.77%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$1.4B
247M shares
52-week range
$3.74 – $8.40
32% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Price (6 mo)
Loading chart…
Change$-2.35
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.6M | $5.3M | $7.6M | $10.1M | $52.2M | $124.5M | $333.6M | $407.3M |
| Cost of revenue | $466.0K | $600.0K | $145.0K | $1.0M | $4.1M | $17.8M | $50.6M | $42.6M |
| Gross profit | $2.1M | $4.7M | $7.4M | $9.1M | $48.0M | $106.7M | $283.1M | $364.7M |
| Gross margin | 82.1% | 88.6% | 98.1% | 90.1% | 92.1% | 85.7% | 84.8% | 89.5% |
| R&D | $69.4M | $71.7M | $65.1M | $91.1M | $35.2M | $35.5M | $52.3M | $68.5M |
| Operating income | −$90.9M | −$91.3M | −$90.8M | −$154.3M | −$63.8M | −$63.3M | −$27.9M | −$41.0M |
| EBITDA | −$85.1M | −$84.6M | −$85.2M | −$150.9M | −$61.0M | −$55.4M | −$16.7M | −$29.2M |
| Net income | −$91.3M | −$94.9M | −$94.3M | −$158.2M | −$67.2M | −$66.1M | −$39.1M | −$61.6M |
| Net margin | -3502.0% | -1797.8% | -1245.7% | -1566.5% | -128.9% | -53.1% | -11.7% | -15.1% |
| EPS (diluted) | -1.62 | -1.47 | -1.05 | -1.52 | -0.42 | -0.30 | -0.17 | -0.26 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $544M | $-0.05 | $-0.13–$0.02 | 8 |
| 2027 | $740M | $0.49 | $0.28–$0.64 | 7 |
| 2028 | $984M | $1.16 | $0.72–$1.50 | 7 |
| 2029 | $1.3B | $1.82 | $1.72–$1.91 | 2 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Ardelyx, Inc.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
www.ardelyx.com- Employees
- 489
- IPO / List date
- Jun 19, 2014
- HQ
- FREMONT, CA
Held by traders on TradeandTell
No one on the platform currently holds ARDX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,272,441 | $7.6M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ARDX yet.
